Abstract
Background: Psoriasis vulgaris is a common chronic inflammatory skin disease that significantly impacts patients’ quality of life. Approximately 30% of patients with moderate to severe psoriasis achieve PASI 75 reduction at 16 weeks after utilizing oral apremilast. Clobetasol, a potent topical steroid, is effective at achieving rapid PASI 75 reduction at 4 weeks but is not a long-term option because of its potential to cause skin atrophy and adrenal suppression. This study investigated whether an initial 6-week tapering regimen of clobetasol spray could improve PASI 75 and sPGA response at 16 weeks in patients with moderate to severe psoriasis who initiate apremilast.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
